MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Dexamethasone Sodium Phosphate, USP	TBD					
Sodium Metabisulfite, NF	0.100	g				
Benzalkonium Chloride Solution (50%), NF	0.04	mL				
Sodium Chloride, USP	0.88	g				
Sterile Water for Injection, USP	80.0	mL				
Sterile Water for Injection, USP	q.s. to 100.0	mL				
Sodium Hydroxide 10% Solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive *(protect from light whenever possible):*	*Sodium Metabisulfite, Benzalkonium Chloride Solution*
Hygroscopic *(protect from moisture whenever possible):*	*Dexamethasone Sodium Phosphate, Benzalkonium Chloride Solution*
Air Sensitive *(protect from air whenever possible):*	*Benzalkonium Chloride Solution. Sodium Metabisulfite*
Metal Reactive *(do not allow to come into contact):*	*Benzalkonium Chloride Solution*
Heat Sensitive *(protect from heat whenever possible):*	*Dexamethasone Sodium Phosphate*
Moisture Sensitive *(protect from humidity whenever possible):*	*Sodium Metabisulfite*

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800* when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Compounder needs to verify as per USP, if every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Dexamethasone Sodium Phosphate, USP §	TBD				
Sodium Metabisulfite, NF §	0.100	g			
Benzalkonium Chloride Solution (50%), NF §	0.04	mL			
Sodum Chloride, USP §	0.88	g			
Sterile Water for Injection, USP §	80.0	mL			
Sterile Water for Injection, USP §	q.s. to 100.0	mL			
Sodium Hydroxide 10% Solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction **IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**	
1.	**Equipment sterilization:** Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

2. **Ingredient quantification:**

A. Determine the potency of Dexamethasone Sodium Phosphate based on the certificate of analysis:

	100%
MINUS	
The Sum of Water content and Alcohol content (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Quantity of water-free and alcohol-free Dexamethasone Sodium Phosphate, in decimal	_____
MULTIPLIED BY	
Assay on Water-free and Alcohol-free basis result (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Potency of Dexamethasone Sodium Phosphate, in decimal	_____
DIVIDED BY (Sodium to Phosphate conversion)	1.10
EQUALS	
i. Potency of Dexamethasone Sodium Phosphate (phosphate equivalent), in decimal	_____

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

3. **Ingredient quantification:**

A. Determine the quantity (in g) of Dexamethasone Sodium Phosphate required to make a **Dexamethasone Phosphate** 1 mg/mL Injection, batch size (100 mL):

Quantity of **Dexamethasone Phosphate** required for 100 mL	0.100 g
DIVIDED BY	
Potency of **Dexamethasone Sodium Phosphate (phosphate equivalent)**, in decimal (Step 2Ai)	_____
EQUALS	
i. Quantity of Dexamethasone Sodium Phosphate needed for 100 mL	_____ **g**
MULTIPLIED BY	
Processing error adjustments (5 to 9%)	1.05 to 1.09
EQUALS	
ii. Quantity of Dexamethasone Sodium Phosphate needed *plus* processing error adjustments	_____ **g**

4. **Powder-liquid preparation:**

A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (80.0 mL *plus* processing error adjustments):

-Sodium Chloride
-Dexamethasone Sodium Phosphate (amount determined in Step 3Aii)
-Benzalkonium Chloride Solution (50%)
-Sodium Metabisulfite

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

5. **pH testing:**

A. Draw an appropriate amount of the mixture (Step 4A).

B. Test the pH of the sample. It should lie between 7.0 and 8.0.

C. If the pH < 7.0, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.
3. Re-test the pH.
4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 7.0 and 8.0 is obtained.

IMPORTANT: Do not allow the pH to rise above 8.0.

6. **Filling to volume:**

A. Add additional Sterile Water for Injection to the mixture (Step 5) to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specifications: Continuously mix.

End result: Homogeneous liquid-like solution.

7. **Filtering and transferring:**

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing containers (see Packaging requirements). Transfer the remainder into separate dispensing containers. These are to be used as the Test samples for sterility and endotoxins testing.

8. **Filter integrity test:**

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

9. **Terminal Sterilization:**

In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specifications.

10. **Sterility and Endotoxin testing:**

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		24 hours controlled room temperature, 3 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.	Packaging Requirements		Sterile, tightly closed, light-resistant unit-dose injection vials.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.		7	Keep at controlled room temperature, (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).
	2	Keep out of reach of children.		8	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	3	Do not use if product changes color.		9	For injection use only.
	4	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.		10	Protect from light.
	5	Discard in the presence of particulate matter.		11	Cap tightly after use.
	6	For veterinary (equine) use only.		12	Equilibrate to room temperature before use.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dexamethasone Phosphate 1 mg/mL Injection (Solution, 100 mL)	FIN	F 007 098v3

REFERENCES

1. Parenteral Preparations. In: Allen, LV, Jr. *The Art, Science and Technology of Pharmaceutical Compounding Fifth Edition.* American Pharmaceutical Association; 2016: 399
2. Dexamethasone-Omega. In: Canadian Pharmacists Association. *Compendium of Pharmacists and Specialties, 2015*: 925.
3. Benzalkonium Chloride. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 7th Edition*. American Pharmaceutical Association; 2012: 60.
4. Sodium Chloride. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 7th Edition*. American Pharmaceutical Association; 2012: 729.
5. Dexamethasone Sodium Phosphate. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 36th Edition.* London, England: The Pharmaceutical Press; 2009: 1526.
6. Dexamethasone (Monograph). In: O'Neil MJ. *The Merck Index 15th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #2945.
7. Dexamethasone Sodium Phosphate. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 5th Edition.* American Pharmaceutical Association; 2012: 154.
8. Dexamethasone Sodium Phosphate (Monograph). *United States Pharmacopeia XXXX / National Formulary 35.* Rockville, MD. US Pharmacopeial Convention, Inc. 2017: 3677.
9. Chapter 8: Buffered and Isotonic Solutions. In: Sinko, D. J. and Singh, Y. *Martin's Physical Pharmacy and Pharmaceutical Sciences, Sixth Edition.* Philadelphia, PA: Lipponcott Williams & Wilkins; 2011: 163-181.
10. Chapter 18: Tonicity, Osmoticity, Osmolality and Osmolarity. In: D.B Troy. *Remington: The Science and Practice of Pharmacy, 21st Edition.* Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265.
11. Dexamethasone. Thomson Micromedex. *USP DI – Drug Information for the Health Care Professional, 26th Edition.* Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 994.
12. USP <797>. *United States Pharmacopeia XXXX / National Formulary 35.* Rockville, MD. US Pharmacopeial Convention, Inc. 2017: 683.